Hôpital d'Instuction des Armées Percy
Clamart, 92140, France
NCT Number: NCT04408001
COVID-19 is a pathology linked to the SARS-CoV-2 virus, a new virus of the coronaviridae family that emerged in China in December 2019 before rapidly becoming a pandemic according to the WHO on March 11, 2020. The epidemic affected France from February 2020. On February 24, a patient hospitalized at Percy hospital was the cause of a major nosocomial epidemic, potentially responsible for more than 250 symptomatic people in the hospital as of April 6. The outbreak was identified by Percy hospital management on March 16, and barrier measures were immediately put in place. From March 20, a mixed investigation unit set up a chain of nasopharyngeal swabs for Percy hospital staff.
A COVID-19 case reporting unit was set up at Percy hospital in response to the identification of the outbreak within the hospital. This unit carried out rapid identification and regular follow-up until the return to work of the staff. Thus all symptomatic patients are identified and the COVID-19 case census cell will follow all Percy hospital staff, including volunteers recruited to deal with the epidemic, throughout the duration of the epidemic. This population, captive by nature, will be one of the few described in the world during this epidemic.
Current data on short-, medium- and long-term immunity induced by COVID-19 infection are fragmentary, as is the existence of a large asymptomatic population, making it difficult to cut the chains of transmission in the absence of an effective diagnostic tool.
Another important issue is the quality of immunity induced by the infection, as it conditions the future of the pandemic, which could become endemic and recurrent if immunity were not sterilizing. As yet unpublished data in primates show that in the primate model re-infection is not possible in the short term, while patients cured from the Wuhan epidemic seem to be detected again positive for virus shedding.
The objective of this study is to characterize the immunity (systemic and local) induced by SARS-Cov-2 infection among Percy hospital staff who are at high risk of contamination even in a period of confinement.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Clamart, 92140, France
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.
At each study visit,
At each study visit, a saliva sample will be collected for the determination of IgA antibodies.
Time frame: At day 21 (compared to enrollment [Day 0])
The presence of induced immunity will be identified by an Ig family switch on the first two serologies with a high titre of specific IgG and disappearance of IgM.
Time frame: 6 months following enrollment
The presence of induced immunity will be identified on serology analysis at 6 months.
Time frame: 1 year following enrollment
The presence of induced immunity will be identified on serology analysis at 1 year.
Time frame: From enrollment (Day 0) to 1 year after enrollement
Kinetics of anti-SARS-CoV-2 antibodies using ELISA technique on serum samples from enrollment (Day 0) to 1 year after enrollement
Time frame: From enrollment (Day 0) to 1 year after enrollement
Kinetics of anti-SARS-CoV-2 antibodies using ELISA technique on saliva samples from enrollment (Day 0) to 1 year after enrollement
Time frame: From enrollment (Day 0) to 1 year after enrollement
Kinetics of serum neutralization against SARS-CoV-2 positive using ELISA technique on serum samples from enrollment (Day 0) to 1 year after enrollement.
Time frame: At enrollment (Day 0)
Anti-SARS-Cov2 seroprevalence measured in serum samples collected at Day 0.
Time frame: At Day 21
Anti-SARS-Cov2 seroprevalence measured in serum samples collected at Day 21.
Direction Centrale du Service de Santé des Armées
Other
Acronym: IMMUNO-COVID
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04353609
Autoimmune Diseases, COVID-19
Lille, France
View Trial DetailsNCT04356495
Corona Virus Infection, Coronaviridae Infections
Bordeaux, France
View Trial DetailsNCT04378842
COVID-19, Coronaviridae Infections
Amiens, France
View Trial DetailsNCT04393974
Cancer, Neoplasms
Brussels, Belgium
View Trial Details